Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth  by Mulholland, David J. et al.
Cancer Cell
ArticleCell Autonomous Role of PTEN
in Regulating Castration-Resistant
Prostate Cancer Growth
David J. Mulholland,1 Linh M. Tran,1 Yunfeng Li,1 Houjian Cai,2 Ashkan Morim,1 Shunyou Wang,1 Seema Plaisier,1
Isla P. Garraway,3 Jiaoti Huang,4 Thomas G. Graeber,1 and Hong Wu1,5,*
1Department of Molecular and Medical Pharmacology and Institute for Molecular Medicine
2Department of Microbiology, Immunology and Molecular Medicine
3Department of Urology
4Department of Pathology
School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095-1735, USA
5Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles,
CA 90095-7357, USA
*Correspondence: hwu@mednet.ucla.edu
DOI 10.1016/j.ccr.2011.05.006SUMMARYAlteration of the PTEN/PI3K pathway is associated with late-stage and castrate-resistant prostate cancer
(CRPC). However, how PTEN loss is involved in CRPC development is not clear. Here, we show that castra-
tion-resistant growth is an intrinsic property of Pten null prostate cancer (CaP) cells, independent of cancer
development stage. PTEN loss suppresses androgen-responsive gene expressions bymodulating androgen
receptor (AR) transcription factor activity. Conditional deletion of Ar in the epithelium promotes the prolifer-
ation of Pten null cancer cells, at least in part, by downregulating the androgen-responsive gene Fkbp5 and
preventing PHLPP-mediated AKT inhibition. Our findings identify PI3K and AR pathway crosstalk as a mech-
anism of CRPC development, with potentially important implications for CaP etiology and therapy.INTRODUCTION
Prostate cancer (CaP) is the most commonmale malignancy and
a leading cause of mortality in western countries (ACS, 2010).
Androgens are critical both for the development and function of
the normal prostate gland and for the maintenance of CaP cells
that arise from thesecretoryepitheliumof theprostate.Androgens
function through their cognitive receptor, the androgen receptor
(AR). Therefore, therapies for advancedCaP usually involve either
reducing or blocking the production of androgens or antagonizing
the AR and its target genes (Chen et al., 2008). However, all men
with metastatic disease develop resistance to these therapies
and will progress to castration-resistant prostate cancer (CRPC).
AR is expressed in CRPC and may function in an androgen-
independent manner through autocrine signaling or crosstalkSignificance
Resistance to androgen-deprivation therapy is the major hu
understanding the molecular mechanisms underlying CRPC w
come resistance. We found that CaPs initiated by PTEN loss re
ress to CRPC independent of epithelial AR, providing amechan
castration-resistant growth. AR loss or inhibition, on the other
the FKBP5 scaffold protein and PHLPP phosphatase. Our stu
ways may enhance therapeutic efficacy for CaPs initiated by P
792 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.with other prosurvival and proliferative pathways (Attard et al.,
2009a; Montgomery et al., 2008). However, levels of AR are
also heterogeneous and, in some instances, absent from late-
stage diseases (Roudier et al., 2003). Such clinical observations
raise the possibility that loss of AR expression or activity may
serve as an alternative means of escaping androgen withdrawal
or AR-targeted therapies, possibly through concomitant activa-
tion of compensatory signaling pathways. One of the possible
survival and proliferative pathways is the PI3K/AKT/mTOR
pathway, which is negatively regulated by the PTEN tumor
suppressor (Hill and Wu, 2009; Taylor et al., 2010). PTEN loss
occurs frequently during human CaP progression, with up to
70% of late stage samples exhibiting loss of PTEN function or
activation of the PI3K pathway (Taylor et al., 2010). PTEN loss
or activation of the PI3K/AKT pathway leads to enhanced cellrdle for managing patients with advanced CaP. Therefore,
ill be helpful for the design of therapeutic strategies to over-
sult in suppression of AR transcription output and can prog-
ism of escaping the requirement of the androgen/AR axis for
hand, can further activate AKT activity via downregulation of
dy suggests that cotargeting both AR and PTEN/PI3K path-
I3K pathway alterations.
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PTEN Regulation of Prostate Cancer Growthproliferation, survival, and migration (Stiles et al., 2004; Vivanco
and Sawyers, 2002) as well as castration-resistant growth (Gao
et al., 2006; Jiao et al., 2007; Wang et al., 2003).
Progress in defining the mechanisms of CRPC has been
limited due to a paucity of xenograft models and scarcity of
matched human clinical specimens representing castration-
sensitive and castration-resistant disease. Several well-estab-
lished transgenic CaP models, i.e., TRAMP (Greenberg et al.,
1995) and hi-Myc (Ellwood-Yen et al., 2003), have the limitation
that the oncogene is driven by an androgen-dependent
promoter. Therefore, the effect of androgen ablation on CaP
growth is confounded by its effect on transgene expression.
Previously, we established the Pten null CaP model by condi-
tional deletion of Pten in the murine prostatic epithelium and
showed that Pten null CaPs progress with defined kinetics that
mimic histopathological features of human disease (Wang
et al., 2003). We also tested whether the Pten null CaP model
could be used for studying CRPC by surgically castrating mutant
mice at 16 weeks, when invasive adenocarcinoma had already
developed. Despite activation of prosurvival AKT signaling,
Pten null cancer cells are sensitive to androgen withdrawal,
and the cell death index is higher than that of age- and genetic
background-matched WT controls and persists for 5–10 weeks
after castration. However, the cell proliferation index is not
changed in comparison to intact Pten null mice. Such
androgen-independent growth overrides androgen-dependent
cell death and causes castration-resistant growth and invasive
adenocarcinoma (Wang et al., 2003). Therefore, the Pten condi-
tional murine CaP model provides a unique opportunity to
address the mechanism of resistance to androgen ablation
therapy where the oncogenic event is androgen independent.
Using this defined genetic model, we now test whether CRPC
development is cancer stage dependent and whether CRPC
remains dependent on AR signaling in the epithelium.
RESULTS
Early Castration Cannot Prevent PtenNull CaP Initiation
and Castration-Resistant Growth
In our previous work (Wang et al., 2003), we castrated Pten
conditional knockouts after the development of invasive adeno-
carcinoma. However, the androgen-independent proliferative
signal could be either intrinsic to Pten loss or due to other molec-
ular/genetic alterations accumulated during cancer progression.
To separate these two possibilities, we tested whether CRPC
development depends on cancer stage by castrating the mutant
mice at time points corresponding to prostatic epithelial Pten
deletion, hyperplasia, and PIN lesion stages, respectively
(Wang et al., 2003) (Figure 1A). Age- and genetic background-
matched Pten null intact and WT castrated mice were used as
controls, and all animals were sacrificed at 10 weeks of age.
Early castration, particularly when performed at 2 weeks old,
significantly reduced the total prostate volume (data not shown).
However, E-cadherin-positive PIN lesions and localized inva-
sion, judged by loss of smooth muscle actin (SMA) staining,
were clearly evident in the dorsolateral lobes of the mutants (Fig-
ure 1B, arrow). Elevated P-AKT (S473) and P-S6 (S240) were also
observed, coinciding with Pten loss, in mutant mice castrated at
2 or 6 weeks old (Figure 1B; see Figure S1 available online).Proliferation index (percentage [%] of Ki67+ cells and Cyclin
D1+ cells) was significantly increased in mutant prostates,
although counts were less in mice castrated at 2 weeks
compared to those castrated at 6 weeks (Figure 1C). This
suggests that other molecular or genetic events may occur
between 2 and 6 weeks after Pten deletion and collaborate
with PI3K pathway to promote cell proliferation. Nevertheless,
these results suggest that androgen-independent proliferation
is intrinsic to Pten loss, which is consistent with previous studies
(Jiao et al., 2007; Gao et al., 2006).
Pten Null CaPs Are Less Dependent on AR Signaling,
and Pten Loss Can Suppress Androgen-Responsive
Gene Expression
That Pten null CaP cells can proliferate under castrate conditions
suggests that Pten loss may sensitize AR to castrate androgen
levels or even obviate the requirement of androgens. To test
this, we compared the AR-signaling status, defined by the
expression of androgen-responsive genes, in age- and genetic
background-matched Pten null and WT prostates at 0, 3, 6,
and 14 days post-castration (n = 3). To determine the AR-
responsive genes in normal, noncancerous prostate, we
analyzed a previously published data set (Wang et al., 2007)
with two criteria: gene expressions were upregulated or downre-
gulated at least 2-fold post-castration (castration/intact), and
their expressions were reverted upon hormone replacement
(hormone replacement/castration). This led to the selection of
148 androgen-responsive genes, including 47 activated and
101 suppressed genes (Table S1). When compared with pub-
lished human androgen-responsive gene lists (Chauvin and
Griswold, 2004; Nelson et al., 2002), we found many overlaps
(data not shown).
Surprisingly, Pten loss in the epithelium does not sensitize AR
signaling, and to the contrary, it suppresses androgen-respon-
sive gene expression or AR transcriptional output in the intact
mice (Figure 2A, orange brackets). Although the expressions of
androgen-responsive genes are significantly changed in WT
mice after castration, the expressions of the majority of
these genes are similar in Pten null prostates before and after
castration (Figures 2A and 2B; Figure S2A). Strikingly, the overall
AR transcriptional output of 14 day castrated WT prostates
is similar to that of intact Pten null prostates (Figure 2C; Fig-
ure S2A). Using a rank-rank analysis and a hypergeometric
overlap algorithm (Plaisier et al., 2010), we also found this simi-
larity between the global expression profiles of genes altered
in Pten null CaPs (Pten null cancer, WT control) with those
enriched after castration (castration, intact or day 0 control, Fig-
ures S2B and S2C). Together, these results indicate that Pten
loss not only suppresses AR transcriptional output but also
drives the overall gene expression profiles toward a castration-
like phenotype.
To test the relevance of our finding to human CaPs, we
analyzed two public data sets (Lapointe et al., 2004; Taylor
et al., 2010). Human samples were first stratified according to
their PTEN DNA copy number status (PTEN CN; Figure 2D)
and then tested if the murine-derived Ar signature genes are
differentially expressed according to the PTEN CN status. We
found 81 of 148 murine androgen-responsive genes in both
human data sets, including 26 activated and 55 suppressedCancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc. 793
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Figure 1. Early Castration Does Not
Prevent Initiation of Pten Null CaP
(A) Pb-Cre+;PtenL/L mutants were castrated (Cx)
at 2, 4, or 6 weeks and aged to 10 weeks.
(B) Mutants Cx at 2 weeks were evaluated for
carcinoma, PI3K (P-AKT, P-S6) activation coin-
ciding with PTEN loss. Prostates were also eval-
uated for invasiveness based on SMA loss but
maintained E-Cadherin expression (arrow). Scale
bars represent 100 mm.
(C) Cell proliferation, Ki67+; Cyclin D1+ (Cyc D1)
cells, in 2 and 6 week Cx cohorts in comparison to
WT Cx controls (**p < 0.01). Scale bars represent
150 mm. Error bars represent mean ± SD.
See also Figure S1.
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PTEN Regulation of Prostate Cancer Growthgenes (Figure 2D). The two-dimensional comparison illustrates
the consistency between the two human data sets for the differ-
ential expression of the murine-derived androgen-responsive
genes in PTEN CN mutant versus normal cohorts (p value of
the correlation coefficient =2.2e-6), suggesting that overall
suppression of AR output in human CaPs with PTEN CN varia-
tion, is similar to our observation in Pten null mutants. In contrast,
cancers with abnormal copy number (CN) of theMYC oncogene
showed less agreement between the two data sets (p value of
the correlation coefficient =1.1e-4) (Figure S2D), indicating that
suppression of AR transcriptional output may depend on
specific oncogenic events.794 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.PTEN Controls AR-Transcription
Factor Activity by Regulating
EGR1, c-JUN, andEZH2Expression
To determine how PTEN loss leads to
repression of AR output, we used an
inducible system in which PTEN expres-
sion is controlled in a doxycycline-depen-
dent manner in Pten null, PtenDloxp/Dloxp
murinecells (Changet al., 2004). Although
Ar expression is not influenced by PTEN
reexpression, Egr1 and c-Jun transcrip-
tion factor expressions are downregu-
lated within 24 hr upon induced PTEN
reexpression, which were confirmed in
a PTEN-inducible human CaP line, PC3
(Figure 2E; data not shown). Both EGR1
and c-JUN are upregulated in CaPs,
especially CRPC, and can physically
interact with AR, leading to downregu-
lated AR-targeted gene expression and
CaP cell growth in an androgen-depleted
environment (Gitenay and Baron, 2009;
Sato et al., 1997; Yang et al., 2006; Yuan
et al., 2010). Egr1 deletion impairs pros-
tate tumorigenesis (Abdulkadir et al.,
2001). Therefore, we hypothesized that
by negatively regulating EGR1 and
c-JUN expression, PTEN upregulates
AR function. Using network component
analysis (NCA) (Tran et al., 2010), we
deduced the TFAs from the expressionsof their target genes. Both EGR1 and c-JUN TFAs are reduced
uponPTEN reexpression,whereasARTFA is increased24hrafter
PTEN reexpression and EGR1/c-JUN activity changes (Fig-
ure 2E), supporting our hypothesis. The activity of AR was further
examined using two murine CaP models: our Pten conditional
knockout (Wang et al., 2003); and the transgenic mice overex-
pressingmAKT (Majumder et al., 2004). The AR TFAs are signifi-
cantly reduced in bothmodels,which canbe revertedby rapamy-
cin treatment (Figure 2E), suggesting that the mTOR pathway is
involved in PTEN regulation of AR activity.
Besides EGR1 and c-JUN, AR target gene expression is also
inhibited by the ERG transcription factor, a member of the ETS
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Figure 2. PTEN Loss Can Suppress
Androgen-Responsive Gene Expression
(A and B) Expression profile (mean ± SEM) of AR-
activated (A) and -suppressed (B) genes in WT
and Pten-null murine prostates after castration.
(C) Heat map of expression ratios of androgen-
responsive genes in WT (14 day post-castration)
and intact Pten null mutants with respect to intact
WT mice.
(D) Variation in expression of androgen-respon-
sive genes based on PTEN CN in human CaP
samples. Left view is a summary of human
samples based on PTEN CN (the numbers inside
parentheses indicate the number of metastatic
cases); right is a comparative analysis of AR-
activated (red circles) and -suppressed (blue
circles) gene expression values in two human CaP
data sets.
(E) Top view shows gene expression and NCA-
derived activities of EGR1, JUN, and AR tran-
scription factors in induced PTEN expression in
Pten/ cells. Bottom view illustrates the activity
of AR in murine models when the PTEN/AKT/
mTOR pathway was manipulated genetically or
pharmacologically.
(F) Expression (mean ± SD) of Ezh2 (left), and AR
and EZH2 cotarget genes (right) in PIN and cancer
(CAN) stages of Pten null prostate. *p < 0.05;
**p < 0.005.
See also Figure S2 and Table S1.
Cancer Cell
PTEN Regulation of Prostate Cancer Growthfamily whose gene is frequently translocated to the AR-respond-
ing TMPRSS2gene (Yu et al., 2010). ERGactivates EZH2 expres-
sion, amember of the polycombcomplex associatedwith human
CaP (Sellers and Loda, 2002; Varambally et al., 2002), and the
EZH2-mediated dedifferentiation program (Yu et al., 2010).
Ezh2 expression is upregulated in Pten null CaP (Figure 2F; Fig-
ure S2E), and the expressions of several AR and ERG-cotargeted
genes, including Nkx3.1, Mme, and Msmb (Kunderfranco et al.,
2010), are also downregulated in Pten null prostate at PIN and
cancer stages (Figure 2F). Our analyses suggest that PTEN loss
suppressesandrogen-responsivegenesby regulatingARactivity
through multiple coregulators, thereby rendering Pten null CaP
cells less dependent or completely independent of signaling
provided by androgens, hence promoting CRPC growth.
Epithelial AR Is Not Required for the Initiation
and Progression of CaPs Caused by Pten Loss
Having demonstrated thatPten null CaP can proliferate indepen-
dent of androgens, we considered whether CaP can develop inCancer Cell 19, 792–8the absence of AR in the epithelium.
We crossed Pb-Cre+;PtenL/L (Pten null)
mutants with mice carrying the AR condi-
tional allele (ArL) (De Gendt et al., 2004).
Ar deletion led to minimal effects on
prostatic epithelium (data not shown),
similar to previous publications (Simanai-
nen et al., 2007, 2009; Wu et al., 2007).
The resulting Pb-Cre+;PtenL/L;ArL/Y
(Pten null;Ar null) mutants were then
analyzed at the ages of 4–6, 10–14,and >20 weeks (n = 4) and compared to their age- and genetic
background-matched Pb-Cre+;PtenL/L mutants. Pten and Ar
deletion promoted robust in situ, latent adenocarcinoma devel-
opment in the dorsolateral lobes. Overall cancer progression in
the double knockouts was similar to that ofPten single knockout,
as evaluated by localized loss of SMA staining (Figure 3C;
Figure S3A).
The anterior and ventral lobes often showed mosaic patterns
of conditional deletion (Figure S3A), likely due to lower levels of
Cre expression in these lobes (Wu et al., 2001) and less efficient
recombination of the ArloxP allele. This allowed us to directly
compare the effect of Ar deletion on Pten null CaP cells. In
Pten- and AR-deleted regions, we found enhanced nuclear
atypia, cell proliferation (Ki67 staining), and cell death (arrow
in the H&E section) in contrast to AR intact regions (comparing
areas above and below the red dashed lines in the lower panels
of Figure 3A). In Pb-Cre+;PtenL/L;ArL/Y mutants, Pten;AR
adenocarcinomas also appeared less differentiated than
Pten;AR+ regions.04, June 14, 2011 ª2011 Elsevier Inc. 795
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Figure 3. Epithelial AR Is Not Required for
the Initiation of Pten Null CaP
(A) Deletion of epithelial AR in the anterior lobe of
Pten null CaP (Pb-Cre+;PtenL/L;ArL/Y) mutants
and the impact on cell proliferation (Ki67+ cells),
apoptosis (red arrow), and cancer formation
(scale bars, 200 mm [top] and 50 mm [bottom]).
(B) Cell proliferation (left) and apoptotic indexes
(right) in Cre (C-), Pb-Cre+;ArL/Y (C+;Ar);
Pb-Cre+;PtenL/L (C+;Pt) and Cre+;PtenL/L;ArL/Y
(C+;Pt;Ar) mutants.
(C) Frequency of invasiveness based on SMA
breakdown in Pb-Cre+;PtenL/L and Cre+;PtenL/L;
ArL/Y mutants during progression. Error bars
represent mean ± SD.
See also Figure S3.
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PTEN Regulation of Prostate Cancer GrowthWe then examined the content of cells positive for the basal
cell markers, p63 and cytokeratin 5 (CK5). We found that
Pten;AR cancers had a significant expansion of p63+ cells in
the proximal region, known to be enriched for stem/progenitor
cells (Figure S3B, bottom) (33.5% versus 15.5% of total cells;
*, p < 0.05), accompanied by increased CK5+;CK8+ transient-
amplifying and p63+;Ki67+ double-positive cells (Figure S3B).
Conversely, the distal regions of Pb-Cre+;PtenL/L;ArL/Ymutants,
which compose the bulk of the tumor mass, contained low or no
p63+ cells, similar to human CaP (Figure S3C). Proliferation and
apoptotic indexes were also increased in Pten null;AR null
cancers (*p < 0.05), most notably in the proximal regions of the
dorsal-lateral lobe (Figure 3B). Despite this, AR-independent
cell proliferation appeared to override AR-dependent cell death,
similar to Pten null cancers under castration conditions (Wang
et al., 2003), resulting in overall AR-independent tumor growth.796 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.Cell Autonomous Role of PTEN
and PTEN-Controlled Pathway
in Regulating AR-Independent
Growth
The mosaic patterns of AR deletion in
Pb-Cre+;PtenL/L;ArL/Y prostates can
potentially complicate our conclusions
because AR+ epithelium may supply
paracrine factors to ‘‘feed’’ the adjacent
AR cells. Thus, we employed prostate
tissue regeneration assays. We used
FACS to enrich for prostate epithelium
from PtenL/L (n = 6) and PtenL/L;ArL/Y
(n = 4) mice, then infected them with
either Cre lentivirus (Cre-FUCRW) or
control lentivirus (FUCRW). Infected
prostate epithelium combined with WT
urogenital mesenchyme (UGSM) was
grafted under the kidney capsule of
NOD;SCID;IL2rg null mice (Figure 4A).
Recombinants were examined for the
presence of pathology coinciding with
Cre-FUCRW or FUCRW infection, as
visualized by the expression of viral-
associated RFP reporter gene (Fig-
ure S4A). PtenL/L;ArL/Y cells infectedwith Cre-FUCRW generated neoplastic pathology with high
levels of P-AKT and P-S6 (Figure 4B), similar to the PtenL/L Cre
virus infection control (Figures S4A and S4B), whereas PtenL/L;
ArL/Y cells infected with control FUCRW virus displayed normal
acinar structure (Figure S4C).
One explanation for our observation is that epithelial cells iso-
lated from the PtenL/L;ArL/Y prostate have been ‘‘primed’’ by
paracrine factors secreted by AR+ stroma cells (Cunha et al.,
2002). To further affirm the cell autonomous role of PTEN in
CaP initiation in the absence of epithelial AR, we carried out
prostate tissue regenerations using prostate epithelium isolated
from E16–17 PtenL/L;Tfm mutant mice obtained from crossing
thePtenL/L conditional line with the Tfmmutantmice. Tfmmutant
mice express a rapidly degraded AR mutant resulting in
complete blockage of prostate development (Cunha and Chung,
1981). Therefore, prostate epithelium of E16–17 PtenL/L;Tfm
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Figure 4. Epithelial AR Is Not Required for
Transformation by Pten Deletion or Myris-
toylated Akt in Regeneration Assays
(A) Evaluating the impact of Cre-mediated deletion
of Pten and Ar on histopathology and PI3K
signaling. The top panel shows the outline of the
experiment, and the bottom panels show results of
tissues stained as indicated. Scale bars represent
100 mm.
(B) Evaluating AR deletion and myristoylated AKT
expression in primary Pb-Cre+;ArL/Y mutants and
the impact on prostate histopathology and PI3K
signaling. The top panel shows the outline of the
experiment, and the bottom panels show results of
tissues stained as indicated. Scale bars represent
200 mm [top] and 50 mm [bottom].
See also Figure S4.
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PTEN Regulation of Prostate Cancer Growthmice should have never been exposed to such potential para-
crine factors. We found that PtenD/D;Tfm epithelial cells formed
PIN lesions with activated AKT (Figure S4D; n = 3). Therefore,
using two in vivo tissue recombinant models, our data indicate
that AR-independent carcinogenesis is intrinsic to PTEN
inactivation.
To further assess whether it is PTEN or the PTEN-controlled
signaling pathway that renders CaP development without
epithelial AR, we orthotopically injected LSL-AKT virus directly
to the anterior lobe of Pb-Cre+;ArL/Y prostates (n = 3) (Figure 4B).Cancer Cell 19, 792–8Using this strategy, only regions express-
ing Cre and infected by lentivirus (indi-
cated by GFP+ expression in Figure 4B
and Figure S4E) will coordinately delete
AR and express Myr-AKT. Although AR+
regions did not show AKT hyperactivation
and abnormal phenotypes (Figure 4B,
arrows in lower panels), AR-deleted
neoplastic regions were pan-cytokeratin
positive and showed higher levels of
P-AKT (Figure 4B, arrowheads in lower
panels). These data support our hypoth-
esis that neoplastic transformation of the
prostate by activated cell autonomous
PI3K/AKT signaling can occur in the
absence of epithelial AR.
AR Downregulates AKT Activity
by Stimulating FKBP5 and PHLPP-
Mediated AKT Dephosphorylation
Postnatal epithelial AR deletion sensitizes
prostate epithelium to paracrine signaling
mediated by AR+ stroma, leading to
androgen-induced epithelial hyperprolif-
eration (Cunha, 1994; Cunha et al.,
2002; Niu et al., 2008a; Simanainen
et al., 2009). To block potential stroma-
derived androgen-induced mitogenic
signals, we castrated Pb-Cre+;PtenL/L;
ArL/Y mutants at 6 weeks (n = 4) and
analyzed their response. Similar to Ptennull mutants, Pb-Cre+;PtenL/L;ArL/Y prostates did respond to
castration but developed castration-resistance when analyzed
4 weeks later. Histopathological analysis indicated that castra-
tion-resistant cancer outgrowths in the dorsolateral lobes are
composed mainly of Pten;AR epithelium (data not shown),
whereas anterior and ventral lobes contained both AR+ and
AR regions (Figure 5A). Strikingly, in comparison to AR+ regions
(arrowheads), AR regions (arrows) containmuch higher levels of
membranous P-AKT and intracellular P-S6 as well as elevated
cell proliferation and cell death, whether assessed at 4 weeks04, June 14, 2011 ª2011 Elsevier Inc. 797
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Figure 5. AR Downregulates AKT Activity
by Stimulating FKBP5 and PHLPP-Medi-
ated, AKT Dephosphorylation
(A) PI3K activation (P-AKT, P-S6) in AR+ regions
(arrows) versus AR regions (arrowheads) in
castrated Pb-Cre+;PtenL/L;ArL/Y mutants (scale
bars, 150 mm [low magnification] and 75 mm [high
magnification]).
(B) Effect of AR deletion on FKBP5 expression in
Pb-Cre+PtenL/L;ArL/Ymutants (scale bars, 50 mm).
(C and D) Expression of FKBP5, PHLPP, and
P-AKT in AR+ regions (arrowheads) compared to
AR null regions (arrows) in castrated Pb-Cre+;
PtenL/L;ArL/Y mutants at 2 days (C) and 4 weeks
(D) after castration (scale bars, 75 mm).
See also Figure S5.
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Figure S5A).
In searching for androgen-responsive genes that are
decreased during castration, we found FKBP5, a member of
the cis-trans prolyl isomerase family (Ratajczak et al., 2003).
FKBP5 is an established androgen-regulated gene in humans
(Magee et al., 2006; Mostaghel et al., 2007) whose expression
is immediately suppressed after castration but upregulated
upon hormone replacement in the WT mouse prostate (Fig-
ure S5B) and downregulated in the Pten null intact and castrated
prostates (Figure S5C), similar to Mme and Msmb (Figure S5D).
We found that FKBP5 expression in Pb-Cre+;PtenL/L;ArL/Y pros-
tate correlates with AR expression (Figure 5B). A recent study
showed that FKBP5, by serving as a scaffolding protein for
AKT and PHLPP, promotes PHLPP dephosphorylation of AKT
at amino acid S473 (Brognard et al., 2007; Gao et al., 2005)
and thereby suppresses AKT activity (Pei et al., 2009). In cas-
trated Pb-Cre+;PtenL/L;ArL/Y prostates, we found that regions
with Pten and AR deletion have hyperphosphorylated AKT
(S473) and reduced PHLPP, especially membrane-associated
PHLPP (Figures 5C and 5D, arrows), whereas Pten;AR+ regions798 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.showed the opposite effect (Figures 5C
and 5D, arrowheads). These results
suggest that downregulation of FKBP5
either by castration or AR loss could
release FKBP5-PHLPP-mediated sup-
pression of AKT activity and promote
AKT-dependent but androgen- and AR-
independent cell proliferation.
Correlations among PTEN, AR,
FKBP5, and PHLPP in Human CaPs
To assess the relevance of our finding to
human CaPs, we took consecutive
sections from a whole-mounted, fresh,
surgically resected human CaP sample
and performed IHC analyses for PTEN,
AR, FKBP5, PHLPP, P-AKT, P-S6, and
Ki67 levels. We observed considerable
heterogeneity of AR expression in PTEN
null cancerous regions (Figure 6A,
arrow) (PTEN;AR+ staining, arrow,
PTEN;AR staining, arrowhead), whereas adjacent noncancer
regions showed uniformed PTEN+ and AR+ staining (Figure S6A).
Importantly, high AR expression regions are associated with
higher FKBP5 and PHLPP but lower P-AKT and P-S6, similar
to our observations in the murine model (Figure S6B). We then
took 40 high-power images from benign and PTEN-negati-
ve;AR-low/negative cancer regions and scored the expression
of PTEN, AR, FKBP5, PHLPP, P-AKT, P-S6, and P-4EBP1 in
a range of 0–3, with 3 being the highest expression level. Similar
to thePb-Cre+;PtenL/L;ArL/Ymousemodel (Figure 6B, left panel),
we observed moderate to high levels of PI3K pathway effectors
in PTEN-negative;AR-low/negative human cancer regions (Fig-
ure 6B, right panel). Moreover, PTEN-negative;AR-low/negative
regions maintained elevated cell proliferation in comparison to
benign regions (19.2% versus 1.4%; p < 0.01) (Figure S6C).
We then surveyed CaP tissue microarrays (TMAs) generated
by the UCLA Prostate SPORE program. Again, consecutive
sections were used for IHC analyses, and only cores showing
>30% epithelia were scored. Among 91 cores we analyzed, we
found extensive heterogeneous AR expression levels, ranging
from nearly 100% AR+ to complete AR (Figure S6D). Using
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Figure 6. Heterogeneous AR Expression in
Human CaPs Correlating with PI3K/AKT
Signaling and FKBP5 and PHLPP Levels
(A) PTEN and AR expression in human CaP (scale
bars, 500 mm).
(B) PI3K pathway components (P-AKT, P-S6, P-
4EBP1) in Pten;AR regions of Pb-Cre+;PtenL/L;
ArL/Ymice and in PTEN-negative;AR-low/negative
regions of human CaPs. Error bars, mean ± SD.
(C) Unsupervised clustering analysis of PTEN,
PHLPP, AR, and FKBP5 in human TMA samples
(n = 91) (left). Chi-square test p values (n = 91) were
used to quantitate the strength of association
between each pair (right, table). Protein level was
categorized to high (IHC >1) and low (%1) levels).
See also Figure S6.
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cantly correlated to PHLPP expression (p = 1.73e-7, c2 test),
whereas AR and FKBP5 are closely clustered together (p =
1.67e-3, c2 test) (Figure 6C; Figure S6E). These data suggest
that the AR-FKBP5-PHLPP feedback loop may also function in
human PTEN-negative;AR-low/negative CaP.
Combined AR/Androgen Ablation and mTOR Inhibition
Results in Enhanced Therapeutic Efficacy in Pten
null CaP
Because ablation of the AR/androgen-signaling axis further acti-
vates AKT, we hypothesized that cancers with low levels of AR
and PTEN loss would have greater dependency on the PI3K/
AKT/mTOR-signaling axis. To test this in vitro, we used CaP8
cells, a Pten null;AR+ cell line derived from the Pb-Cre+;PtenL/L
CaP model (Jiao et al., 2007), infected with either a scramble
or a sh-AR RNAi lentivirus containing a RFP tag for FACS.
Analysis of cell viability at 0, 2, 4, and 6 days indicated a co-
operative reduction in cell viability using AR knockdownCancer Cell 19, 792–8combined with the mTOR inhibitor rapa-
mycin (1 nM) (Figure 7A, left graph) (n =
6). We also treated the PTEN null;AR+
LNCaP human CaP cell line with rapamy-
cin (1 nM), the second-generation anti-AR
inhibitor MDV3100 (10 mM) (Scher et al.,
2010; Tran et al., 2009), or both. Again,
we observed a cooperative inhibition
effect when both AR and PI3K/mTOR
pathways were targeted (Figure 7A, right
graph) (n = 6).
To test our hypothesis in vivo, we
treated intact and castrated Pb-Cre+;
PtenL/L and Pb-Cre+;PtenL/L;ArL/Y mice
at cancer stage with rapamycin and eval-
uated the effects by Ki67 index (Fig-
ure 7B) and histopathology (Figure 7C;
Figure S7; n = 4). Rapamycin treatment
(4 mg/kg daily for 4 weeks) led to
a reduction of Ki67 index in Pb-Cre+;
PtenL/L intact mutants from 17% to 11%;
castration and castration plus MDV3100
(10 mg/kg/day) further reduced therates of cell proliferation to 8% and 3%, respectively (Fig-
ure 7B). Similarly, when Pb-Cre+;PtenL/L;ArL/Y mutants were
castrated and treated with or without rapamycin for 4 weeks,
we found a significant reduction of prostate volume in compar-
ison to the placebo cohort (Figure 7C). At the histological
level, double mutants with rapamycin treatment showed
significant atrophy in most glandular structures, similar to
that of WT castrated and Pten null castrated mice treated
with combination of rapamycin and MDV3100 (Figure S7).
A reduction in P-S6 (Ser240) staining and reduced cell pro-
liferation (Figures 7B and 7D) (33.7% versus 4%; **p < 0.01)
were also observed. Interestingly, many residual epithelia in
rapamycin-treated castrated mutants appeared to be AR+
(high-power inset). Collectively, these data suggest that
CaPs with AR loss have greater reliance upon the PI3K/AKT/
mTOR-signaling pathways and that combined AR/androgen
blockage in conjunction with PI3K/AKT/mTOR inhibition is
more effective for CaPs initiated by PTEN loss or PI3K/AKT
activation.04, June 14, 2011 ª2011 Elsevier Inc. 799
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Figure 7. Cooperative Effects of AR and
mTOR Inhibition In Vitro and In Vivo
(A) In vitro response of Pten null;Ar+ murine (CaP8)
and human (LNCaP) prostate cancer cells to AR
knockdown (sh-AR) or pharmacological inhibition
of AR (MDV3100, 10 mM) with and without rapa-
mycin (R: 1 nM) treatment (Sc, control sh oligo).
(B and D) In vivo response to treatments with
castration, MDV3100, rapamycin, or their combi-
nations as measured by cell proliferation (Ki67+
cells) and (C and D) tumor burden in Pb-Cre+;
PtenL/L and Pb-Cre+;PtenL/L:ArL/Ymutants. Scale
bars represent 2 mm (C), 200 mm (D), and 75 mm
(D, inset). Error bars represent mean ± SD.
See also Figure S7.
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PTEN loss or PI3K pathway activation represents one of themost
frequent genetic alterations found in human CaPs (Taylor et al.,
2010). Dysregulation of the PTEN/PI3K pathway has also been
associated with resistance to conventional antiandrogen thera-
pies (Ham et al., 2009). Despite these clinical observations,
the consequence of PTEN loss and how its loss influences
the androgen/AR-signaling axis and CRPC development is
unclear. By genetically deleting Pten and Pten/Ar in the prostatic
epithelium and analyzing human CaP samples, our studies
support the hypothesis that PTEN loss or PI3K pathway activa-
tion may function in a cell autonomous manner to promote
androgen/AR-independent CaP progression and CRPC devel-
opment. Although Pten null epithelial cells remain sensitive to
androgen withdrawal or AR ablation, the resulting activated
PI3K/AKT pathway is sufficient to compensate for androgen/
AR-signaling blockage, mobilize basal and transient-amplifying800 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.stem/progenitor cells, and promote cell
proliferation. Therefore, in CaPs initiated
by PTEN loss or PI3K activation, the
overall outcome of cancer development,
especially CRPC development, depends
on the balance of androgen-dependent
cell survival/differentiation and andro-
gen-independent cell proliferation. PTEN
loss enhances the expressions of
EGR1, c-JUN, and EZH2, which in turn
suppresses AR TFA and output. Inhibiting
FKBP5/PHLPP-mediated negative feed-
back to AKT activation, as a result of
castration or AR inhibition, may further
enhance the strength of the PI3K/AKT
pathway and tilt the balance toward
androgen-independent growth (Figure 8).
Importantly, results derived from our
genetically engineered mouse models,
including PTEN-controlled AR transcrip-
tion output and AR-FKBP5-PHLPP regu-
latory loop, can also be observed in
humanCaP samples.Given the heteroge-
neous PTEN deletion/mutation and AR
expression patterns within individualhuman CaPs, shown in our study and by others (Attard et al.,
2009b; Taylor et al., 2010), we would expect to observe a broad
range of phenotypes correlating between PTEN loss, AR expres-
sion, and CRPC development in human patients.
Using genetically engineered animal models, our findings
may provide potential insight into the clinical settings. Although
hormone therapy immediately after radical prostatectomy
improves survival and reduces recurrence (Messing et al.,
1999), it is not clear whether early androgen-deprivation
therapy (ADT) will prevent cancer progression and CRPC
development. That early castration of the Pten null CaP model
does not significantly impede carcinoma development and
castration-resistant growth suggests that patients with PTEN
loss or PI3K pathway activation may not benefit from aggres-
sive early hormone treatment. Although neoadjuvant ADT
may partially reduce tumor load and PSA levels, it may select
for cells with activated compensatory cell survival and prolifer-
ating signaling pathways, such as those PTEN null or PI3K/AKT
Figure 8. PTEN Loss Promotes CRPC Development by Two Collab-
orative Mechanisms
By regulating EGR1, c-JUN, and EZH2 expression and activities, PTEN loss
suppresses AR TFA and output, leading to reduced prostate epithelial differ-
entiation and survival. Collaboratively, PTEN loss activates the PI3K/AKT-
signaling pathway and reduces the AR-regulated FKBP5-PHLPP negative
feedback loop, further enhancing AKT activation, leading to androgen/AR-
independent prostate epithelial proliferation.
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PTEN Regulation of Prostate Cancer Growthactivated, and ultimately facilitate resistance to antiandrogen
therapy.
An important finding from our study is that PTEN loss
suppresses AR TFA and androgen-responsive gene expression
in both murine models and human prostate samples. Interest-
ingly, AR itself is not downregulated in Pten null CaPs, even after
castration (data not shown), similar to human cancers after
short-term castration or after 9 months of neoadjuvant ADT
(Mostaghel et al., 2007). Previous studies suggest that the
PI3K pathway can either activate or suppress AR activity (Kaarbo
et al., 2010; Lei et al., 2006; Lin et al., 2003, 2004). Our analyses
demonstrate that PTEN, through regulating the expressions and
activities of EGR1 and c-JUN transcription factors and EZH2
levels, controls AR transcription output. This results in PTEN
null CaP cells being less or completely independent of signaling
provided by androgens and epithelial AR, hence promoting
castration-resistant growth. However, how the PTEN/PI3K
pathway controls EGR1, c-JUN, and EZH2 expression and activ-
ities requires further study.
The mosaic pattern of AR deletion observed in our in vivo
model also mimics the heterogeneous AR expression observed
in our human CaP studies and those reported by others (Attard
et al., 2009b). After castration of Pb-Cre+;PtenL/L;ArL/Ymutants,we observed significant outgrowth of Pten;AR cancerous
regions, accompanied by elevated P-PAKT and cell proliferation.
Adjacent to these outgrowth are AR+ regions. Therefore, it is
possible that within heterogeneous malignant CaPs, those with
low or negative AR expression fail to respond to conventional
antiandrogen treatment and continue to proliferate and survive
as a consequence of PTEN loss and PI3K/AKT activation.
Although such cells would not constitute PSA-producing cancer
cells, they would contribute toward overall tumor load.
An intriguing finding of our study is the elevated P-AKT (S473)
levels, despite genetic deletion of Ar and surgical castration.
The recently defined relationship between FKBP5 and the AKT
phosphatase, PHLPP (Gao et al., 2005; Brognard et al., 2007;
Pei et al., 2010), provides a potential mechanism as to how PI3-
K/AKT signaling can be activated upon inhibiting the AR/
androgen-signaling axis. Specifically, in normal cells PHLPP
levels are high, which keeps P-AKT levels low, downregulation
of FKBP5 in Pten cells that have undergone AR/androgen
ablation would lead to a reduction of PHLPP’s association
with P-AKT and, consequently, enhance AKT activity. Although
it is difficult to assess P-AKT levels in all human CaP samples
due to various sample harvesting and preparation procedures
used, we did observe statistically significant correlation
between the levels of PTEN and PHLPP as well as AR and
FKBP5. Importantly, when a fresh resected CaP sample was
analyzed, we found that regions with low or no AR expression
had lower levels of FKBP5 and PHLPP and enhanced P-AKT
and P-S6 staining. Besides the AR-FKBP5-PHLPP feedback
loop, we also observed changes in other scaffold proteins and
mediators of the PI3K pathway (Table S1). It will be interesting
for future studies to ascertain whether other AR/androgen-regu-
lated genes, such as FKBP11 and IGFBP3/6, also have the
capacity to modulate PI3K/AKT signaling in a manner similar
to FKBP5.
Increasing evidence suggests that different cellular compart-
ments may contribute differently toward cancer initiation. For
example the prostate epithelial AR may confer some suppressor
function, whereas the stromal AR has been postulated to be
mitogenic (Cunha et al., 2002; Simanainen et al., 2009), thus
raising the possibility that stromal AR plays a dominant role in
Pten null cancer initiation or during the development of CRPC.
In fact, using the TRAMP CaP model, a previous report has
shown that reduction of stromal AR content may lead to reduced
tumor progression (Niu et al., 2008b). However, extrapolating
these data to human disease is challenging because the neuro-
endocrine carcinoma found in the TRAMP model is a phenotype
not commonly observed in human disease (Abbas et al., 1995;
Tetu et al., 1987). It is also possible that while AR loss or
degradation in differentiated luminal epithelium results in cell
death, AR loss in basal or transient-amplifying initiating cells is
well tolerated. In fact recent reports have shown that the basal
‘‘LSC’’ stem/progenitor cells either from the Pten null CaPmodel
(Mulholland et al., 2009) or from primary human tissue that has
been transformed (Goldstein et al., 2010) are sufficient for tumor
reconstitution. Thus, it would be interesting and potentially clin-
ically relevant to ascertain if AR null stem progenitor cells would
be capable of cancer initiation. Interestingly, cells with high
N-cadherin expression, a marker associated with epithelial-
mesenchymal transition and cancer metastasis at late-stageCancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc. 801
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PTEN Regulation of Prostate Cancer Growthdisease, are also low or null for AR. Moreover, forced expression
of N-cadherin results in reduced AR expression and elevated
P-AKT in human CaPs (Tanaka et al., 2010).
Previous studies have shown that mTOR inhibition alone is
relatively ineffective at reducing overall tumor load in Pb-Cre+;
PtenL/L mutants (Kinkade et al., 2008; Zhang et al., 2009). To
test the hypothesis that combined AR and mTOR targeting
may be more effective where single-agent use is not, we evalu-
ated the impact of total AR/androgen ablation in conjunction
with mTOR inhibition. When comparing Pb-Cre+;PtenL/L;ArL/Y
mutants under castration alone to those with rapamycin, we
observed marked inhibition of cell proliferation and reduction
of tumor load. Thus, these preclinical data suggest that complete
abolishment of the AR/androgen-signaling axis combined with
mTOR inhibition is superior to single-agent use, most likely by
inhibiting the crosstalk between the two pathways. Thus, more
effective blockade of the androgen/AR axis with new generation
inhibitors such as abiraterone andMDV3100 in combination with
mTOR or PI3K/mTOR dual inhibitors may prove to be further
advantageous in treating CRPC cases initiated by alterations of
PTEN/PI3K pathway.EXPERIMENTAL PROCEDURES
Generation of Pb-Cre+;PtenL/L;ArL/Y and PtenL/L;Tfm Mutant Mice
Mice with conditional deletion of Pten and AR in the murine prostate were
developed by crossing male Pb-Cre+;PtenL/L mice with Cre;ArL/ArL female
mice on a mixed background. The AR conditional line (ARloxP-exon2-loxP) was
obtained from and previously described by the laboratory of Dr. Guido Verho-
even (De Gendt et al., 2004), whereas Pb-Cre+;PtenL/L mutants were
described by our laboratory (Wang et al., 2003). PtenL/L;Tfm mutant mice
were obtained by crossing PtenL/L mutants with Tfm mice (JAX) (Cunha and
Chung, 1981). All animal experiments were approved by the UCLA Animal
Research Committee and conducted according to relevant regulatory
standards.
Cell Isolation and Flow Cytometry
The isolation of murine prostate epithelium was carried out by mechanical
dissociation (5 min mincing) and enzymatic digestion (collagenase type I
digestion at 37C for 2 hr) of all prostate lobes. Single-cell suspensions were
generated and stained in DMEM 10% FBS for 20 min at 4C with anti-CD49f
(BioLegend), and with a Lin cocktail comprised of anti-CD45, anti-CD31,
and anti-Ter119 (eBioscience). Cell sorting was performed on the BD FACS
Vantage or BD FACS Aria II (BD Biosciences). Lin-CD49fhi/mid cells were
collected and subsequently used for FACS analysis and/or tissue regeneration
assays (Mulholland et al., 2009).
Prostate Regenerations
Donor (Lin-CD49fhi/mid) epithelia isolated from Cre, Cre;PtenL/L, or Cre;
PtenL/L;ArL/Y, or PtenL/L;Tfm mutant mice were infected with high-titer
(>1 3 109) Cre-lentivirus (Cre-FUCRW) by low-speed centrifugation over
90 min. Infected epithelia (1–2 3 105) were recombined with UGSM
(2 3 105) in 15 ml collagen pellets and incubated for 6–10 hr in DMEM (high
glucose, 10% FBS; insulin, 0.005 mg/ml; bovine pituitary extract, 10.7 mg/ml;
EGF/FGF, 3.0 ng/ml). Tissue recombinants were then surgically implanted
below the kidney capsule of NOD;SCID;IL2rg null mice for 6–10 weeks
(Mulholland et al., 2009; Lawson et al., 2010; Goldstein et al., 2010).
Plasmids
The murine Ar-specific short hairpin RNAs (shRNA) (Jiao et al., 2007) were
cloned into the BamHI-EcoRI site the lentivector FUCRW under regulation
with a U6 promoter. The open reading frame for the human AR gene with
Flag tag was cloned at the XbaI site under the human ubiquitin promoter.802 Cancer Cell 19, 792–804, June 14, 2011 ª2011 Elsevier Inc.Orthotopic Lentivirus Injection
The LSL-Akt (loxP-RFP-loxP-myr-Akt-Ires-EGP) lentivector and virus were
generated as previously described (Marumoto et al., 2009). To carry out ortho-
topic injections, 2–3 ml of high titer lentivirus (>13 108) was injected to the base
of the anterior prostate lobe (proximal to urethra) of Pb-Cre+;ArL/Y mice aged
2–3 weeks using a cemented, 10 ml microsyringe (Hamilton). Mice were then
aged for 6–8 weeks and subsequently evaluated at the histological level.
Collection of Patient Samples
Clinical sampleswere obtained with informed consent under approval from the
University of California at Los Angeles (UCLA) Institutional Review Board. All
samples were obtained in a deidentified manner to maintain patient
confidentiality.
Human Whole-Mount and TMA
Pathologic specimens (whole-mount specimens) were acquired from the
UCLA Tissue Procurement Core Laboratory in a deidentified manner. IHC
analysis and scoring were carried out on cores containing >30% epithelial
content (Thomas et al., 2004).
Drug Treatment
Pb-Cre+;PtenL/L and Pb-Cre+;PtenL/L;ArL/Y were castrated and immediately
treated with 4 mg/kg/day (i.p.) rapamycin (Selleck Chemicals), 10 mg/kg/day
MDV3100, or vehicle control (p.o.). Mice were treated for 4 weeks and then
evaluated at the histological level.
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Gene expression microarray data have been deposited in the GEO database
with the accession number GSE29010.
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